NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
* Return to Food & Drug Law Alert Section

Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members



November 24th, 2008

   2008 NOV 24 -- The CPF announced that the Pulmonary Fibrosis Research Enhancement Act (PFREA) (H.R. 6567) - which would authorize $16 million in new federal funding for pulmonary fibrosis (PF) research - has now gained the support of 27 Members of the U.S. House of Representatives.

   PFREA is first of its kind legislation to improve research and awareness of pulmonary fibrosis, a terminal lung disease with no known cause, no FDA approved treatment and no cure. (For more information on PF, visit www.coalitionforpf.org). The PFREA is expected to be re-introduced in the 111th Congress in early 2009. However, additional Members of Congress could be added on as co-sponsors in the current Congress if there is a lame duck Congressional session.

   "We are pleased to see the Pulmonary Fibrosis Research Enhancement Act gaining momentum. This bill is critical to finding treatments and saving lives from this devastating disease," said Mishka Michon, Chief Executive Officer of the CPF. "We are thankful for the leadership Brian Baird and Mike Castle have given to this effort."

   Keywords: Fibrosis, Hepatology, Lung Disease, Regulatory Actions, Coalition for Pulmonary Fibrosis.

   This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.

Return to Food & Drug Law Alert Section

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login